Any current/future capex/capital investment/strategic investment?

Raising INR 364 crores through a rights issue for the R32 plant expansion to 10,000 metric tons capacity. CapEx for R32 plant doubled from INR ~200 crores to INR 364 crores due to scale-up. Helium facilities at Khalapur and Mambattu being set up with a total CapEx of INR 15-20 crores funded through internal accruals. Plans for a new plant in Bhilwara with allotted land and associated CapEx (exact amount not specified). Expansion involves setting up integrated chemical process plants with future phases including by-product commercialization and HFO plant. All capital projects backed by interest

Future growth expectations in sales/revenue/volumes?

FY26 revenue guidance is INR 430 crores, with PAT guidance of INR 40 crores. Expect production start of R32 plant with six months production from October 2026 generating about INR 275 crores revenue and INR 66 crores PAT in first year. FY27 revenue target is INR 550 crores and PAT INR 132 crores, combining current business and new facilities. Next year projected turnover around INR 950 crores with full-year R32 production and growth from helium and speciality gases. Long-term (5 years) target for helium and speciality gases revenue is INR 200 crores. Targeting 30-35% CAGR over the next three y

Future growth expectations in earnings/operating earnings/profits/EPS?

Stallion India Fluorochemicals targets a 30-35% CAGR over the next three years driven by backward integration, higher value products, and margin expansion of 3-4%. FY26 revenue guidance is INR 430 crores with PAT guidance of INR 40 crores. For FY27, expected revenue of INR 550 crores from new facilities plus current business, with PAT between INR 180-200 crores combining all operations. New R32 plant (10,000 MT capacity) is expected to achieve 50% production in first six months generating approx. INR 275 crores revenue and INR 66 crores PAT in FY26. Full-year R32 production in FY27 expected to

IN US

Sale is live|00:00:00left today

Stallion India Fluorochemicals LtdQ4 FY27Chemicals & Petrochemicals

Stallion India Fluorochemicals Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹182P/E: 37.3Market Cap: ₹1.6K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 1

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

4 of 4 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 1

→FY26 revenue guidance is INR 430 crores, with PAT guidance of INR 40 crores.
→Expect production start of R32 plant with six months production from October 2026 generating about INR 275 crores revenue and INR 66 crores PAT in first year.
→FY27 revenue target is INR 550 crores and PAT INR 132 crores, combining current business and new facilities.
→Next year projected turnover around INR 950 crores with full-year R32 production and growth from helium and speciality gases.
→Long-term (5 years) target for helium and speciality gases revenue is INR 200 crores.
→Targeting 30-35% CAGR over the next three years, with margin expansion from 10% to 24% PAT.
→Growth supported by backward integration, value-added products, facility expansions (Bhilwara, Khalapur, Mambattu), and market penetration.

Margin guidance

Category 1

→Stallion India Fluorochemicals targets a 30-35% CAGR over the next three years driven by backward integration, higher value products, and margin expansion of 3-4%.
→FY26 revenue guidance is INR 430 crores with PAT guidance of INR 40 crores.
→For FY27, expected revenue of INR 550 crores from new facilities plus current business, with PAT between INR 180-200 crores combining all operations.
→New R32 plant (10,000 MT capacity) is expected to achieve 50% production in first six months generating approx. INR 275 crores revenue and INR 66 crores PAT in FY26.
→Full-year R32 production in FY27 expected to add approximately INR 550 crores revenue and INR 132 crores PAT.
→Long-term target (within 5 years) for helium and specialty gases is INR 200 crores.
→Current EPS for 9M FY26 stood at INR 4.15, up from INR 3.10 YoY, reflecting strong operating momentum and scalability.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

- Stallion India Fluorochemical Limited currently is raising INR 364 crores through a rights issue for the R32 plant expansion (Page 14, 7, 15). - The management expects this to be the last equity dilution; future expansions will mainly rely on debt and warrants (debentures) rather than further equity dilution (Page 12). - The company is currently debt-free but has MOUs signed for project finance with banks and the government of Rajasthan to secure project loans quickly if needed (Page 12). - Internal accruals and the rights issue proceeds are expected to sufficiently cover upcoming CapEx and operations; no present stress on funds (Page 12). - The fund infusion from shares sold by promoters was interest-free and funneled back into the company for kickstarting projects (Page 3). In summary, the near-term fundraising is focused on an equity rights issue with ample backup plans for debt financing if required.

Order book

The transcript does not explicitly mention details about the current or expected order book or pending orders for Stallion India Fluorochemicals Limited. However, relevant insights include: - The company is experiencing significant growth with several new plants and expansions underway (e.g., 10,000 MT R32 plant, helium plants at Khalapur and Mambattu). - Production projections indicate strong revenue growth: INR 430 crore for FY26, INR 675 crore for FY27 with the addition of new facilities, and INR 950 crore expected the subsequent year. - Management expresses confidence in sustaining a 30-35% CAGR over the next three years, supported by backward integration, higher-value products, and margin expansion. - They mention more than 200 customers across 15+ countries, indicating a robust demand pipeline. - The upcoming R32 facility aims for 50% production in the first year, with expected revenues of INR 275 crore in six months. No specific quantitative order backlog or pending orders data is disclosed.

Capex plans

Yes

→Raising INR 364 crores through a rights issue for the R32 plant expansion to 10,000 metric tons capacity.
→CapEx for R32 plant doubled from INR ~200 crores to INR 364 crores due to scale-up.
→Helium facilities at Khalapur and Mambattu being set up with a total CapEx of INR 15-20 crores funded through internal accruals.
→Plans for a new plant in Bhilwara with allotted land and associated CapEx (exact amount not specified).
→Expansion involves setting up integrated chemical process plants with future phases including by-product commercialization and HFO plant.
→All capital projects backed by interest-free funds or project finance; currently debt-free with no anticipated further dilution beyond current rights issue.
→Target to achieve operational milestones within 6-18 months (e.g., R32 plant to start production within 6 months).

How does Stallion India Fluorochemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Stallion India Fluorochemicals Ltd

Rev 1Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Stallion India Fluorochemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio